MIRA PHARMACEUTICALS, INC.

MIRA · Nasdaq · SIC 2834: Pharmaceutical Preparations
85
SEC Filings

Business Summary

PART I ITEM 1. Description of Business Overview MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA, the Company, we, us) is a clinical-stage pharmaceutical development company advancing a pipeline of novel oral therapeutics targeting neurologic, neuropsychiatric, metabolic, and addiction-related disorders. The Company holds exclusive rights in the United States, Canada, and Mexico to Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address significant unmet medical needs across neuropathi...

Next Earnings

Q2 FY2026 — expected 2026-09-16

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionMIRAdiscussed_in_filing Trusted Computing
topic_mentionMIRAdiscussed_in_filing Blockchain & Crypto
topic_mentionMIRAdiscussed_in_filing Capital Expenditure
topic_mentionMIRAdiscussed_in_filing Regulation
topic_mentionMIRAdiscussed_in_filing Healthcare & Bio
topic_mentionMIRAdiscussed_in_filing Trusted Computing
topic_mentionMIRAdiscussed_in_filing Blockchain & Crypto
topic_mentionMIRAdiscussed_in_filing Capital Expenditure
topic_mentionMIRAdiscussed_in_filing Regulation
topic_mentionMIRAdiscussed_in_filing Healthcare & Bio
topic_mentionMIRAdiscussed_in_filing Trusted Computing
topic_mentionMIRAdiscussed_in_filing Blockchain & Crypto
topic_mentionMIRAdiscussed_in_filing Capital Expenditure
topic_mentionMIRAdiscussed_in_filing Regulation
topic_mentionMIRAdiscussed_in_filing Healthcare & Bio
topic_mentionMIRAdiscussed_in_filing Trusted Computing
topic_mentionMIRAdiscussed_in_filing Blockchain & Crypto
topic_mentionMIRAdiscussed_in_filing Capital Expenditure
topic_mentionMIRAdiscussed_in_filing Regulation
topic_mentionMIRAdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001493152-26-014001EDGAR68K words
2025-03-282024-12-310001641172-25-001183EDGAR—
2024-04-012023-12-310001493152-24-012141EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001493152-25-022112EDGAR15K words
2025-08-142025-06-300001641172-25-024077EDGAR—
2025-05-142025-03-310001641172-25-010301EDGAR—
2024-11-122024-09-300001493152-24-044747EDGAR—
2024-08-132024-06-300001493152-24-031612EDGAR—
2024-05-132024-03-310001493152-24-018908EDGAR—
2023-11-132023-09-300001493152-23-040517EDGAR—
2023-09-152023-06-300001493152-23-032778EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-230001493152-26-012085EDGAR1K words
2026-03-030001493152-26-008707EDGAR—
2026-02-020001493152-26-004739EDGAR—
2025-12-220001493152-25-028619EDGAR—
2025-12-050001493152-25-026445EDGAR—
2025-10-230001493152-25-019065EDGAR—
2025-10-160001493152-25-018303EDGAR—
2025-10-150001493152-25-018141EDGAR—
2025-09-300001493152-25-016168EDGAR—
2025-09-220001493152-25-014393EDGAR—

85 total filings indexed. 64 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001904286
TickerMIRA
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedFL

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 5aa6c0697f9f0f4fdf931a2e16873d15873ccc7f90959bd2b0ce6a145d5d0b5a
parent: 40c5c47f9f298f198b5f7d8fa1738ca561d3aa8d6f3256d95985c29862fe8951
content hash: 266fa16de1d75803b5bfa0fa5f23f67a9faa45cd31003bdcb3b742e2e486d9a7
signed: 2026-04-13T04:46:16.531Z
sources: 11 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf